DMT

Binding affinity at 5-HT2AR is lower than that of lsd but correlates with psychoactive doses in humanssupported

DMT: lower 5-HT2A affinity than LSD... Receptor profiles predict hallucinogenic effects similar to classic serotonergic hallucinogens. j.euroneuro.2016.05.001

In rodent models, 5-HT2A receptor activation is the primary mediator of hallucinogenic behavioral responses (head twitch response), with metabotropic glutamate receptor 2 (mGluR2) contributing a modulatory role.supported

5-HT2A and 5-HT2C as primary mechanisms for hallucinogenic drugs including DMT. mGluR2 contribution investigated. s00213-014-3658-3

A mechanistic advance published in 2023 demonstrated that psychedelics, including DMT, promote cortical neuroplasticity specifically through activation of intracellular 5-HT2ARs located on the Golgi apparatus of cortical neurons — not cell-surface receptorssupported

Intracellular 5-HT2ARs mediate plasticity-promoting properties of psychedelics... Location bias in 5-HT2AR signaling identified. science.adf0435

Barker (2025) has proposed that DMT may serve as the endogenous ligand for these intracellular 5-HT2ARs, providing both a psychedelic mechanism and a natural neuroregulatory function.supported

DMT proposed as endogenous ligand for intracellular 5-HT2A in Golgi. Neuroplastogen role. j.pnpbp.2025.111259

It functions as an endogenous agonist at sigma-1 receptors, where it inhibits voltage-gated sodium channels and produces behavioral effects absent in sigma-1 knockout micesupported

DMT bound to sigma-1 receptors and inhibited voltage-gated sodium ion channels... DMT induced hypermobility in wild-type mice but not sigma-1 knockout mice. science.1166127

Sigma-1 receptor activation by DMT confers neuroprotective effects in ischemic modelssupported

DMT mitigated spreading depolarizations via sigma-1R in rat ischemia model. Reduced apoptotic/ferroptotic cells. j.neuropharm.2021.108612

DMT also agonizes 5-HT1A receptors, which may attenuate some 5-HT2A-mediated hallucinogenic effects, and 5-HT2C receptorspartially supported

5-HT2A and 5-HT2C as primary mechanisms for hallucinogenic drugs including DMT. s00213-014-3658-3

At monoamine transporters, DMT behaves as a substrate (not an inhibitor) at both the serotonin transporter (SERT; K_I = 4.00 ± 0.70 µM) and the vesicular monoamine transporter 2 (VMAT2; K_I = 93 ± 6.8 µM), a mechanism that may facilitate intracellular accumulation at its receptor targetssupported

DMT inhibits [3H]5-HT uptake via SERT with KI of 4.00 ± 0.70 µM. High binding-to-uptake ratios support DMT is a transporter substrate not blocker at both SERT and VMAT2. s00702-009-0308-8

DMT produces a robust agonist response at the human trace amine-associated receptor (TAAR), though the functional significance of TAAR activation remains uncertainsupported

DMT: 5-HT1A/2A/2C partial agonism + sigma-1 + TAAR. s00018-024-05353-6

Claim in pharmacology — inconclusiveinconclusiveworking →

The first detailed human IV pharmacokinetic study (SPL026/DMT fumarate, 10-minute infusion, 24 healthy subjects, doses 9–21.5 mg freebase equivalent) yielded a mean elimination half-life of 9–12 minutes with dose-proportional pharmacokineticssupported

24 healthy subjects received escalating IV DMT (9-21.5 mg freebase as 10-min infusion). Mean elimination half-life 9-12 min. s13318-023-00822-y

Psychological effects begin within seconds of IV bolus administration, peak at 90–120 seconds, and resolve nearly completely within 30 minutessupported

Psychological effects began almost immediately after IV administration, peaked at 90-120 seconds, almost resolved by 30 minutes. archpsyc.1994.03950020022002

Continuous IV infusions (0.6–2.4 mg/min over 120 minutes) in 22 healthy participants confirmed dose-proportional PK, with subjective effects plateauing within 30 minutes and moderate acute tolerance developing during sustained infusion.supported

22 healthy participants received placebo and DMT (0.6-2.4 mg/min) over 120 min infusion. Dose-proportional PK, dose-dependent subjective effects plateau at 30 min. Moderate acute tolerance observed. s41386-024-02041-8

Urinary metabolite profiling reveals a shift from MAO-dependent to CYP-dependent metabolism: unmetabolized DMT accounts for 10% of urinary recovery, DMT-N-oxide for 28%, and indole-3-acetic acid (3-IAA) for 63%supported

Smoked route: fully psychoactive, IAA 63%, DMT-N-oxide 28%, unmetabolized DMT 10%. dta.1685

In a large naturalistic survey (n = 3,778), the median smoked dose was 40 mg with a median experience duration of approximately 10 minutes.supported

Qualitative analysis of 3778 Reddit DMT experiences 2009-2018. Median dose 40mg, median duration 10min. s41598-022-11999-8

Without MAO-A inhibition, oral DMT is essentially inactive: 97% of urinary recovery consists of the MAO-A metabolite 3-IAA, and no psychotropic effects occur at 25 mg oralsupported

Oral route: no psychotropic effects, 97% IAA in urine. dta.1685

In a controlled oral PK study, ayahuasca at DMT doses of 0.6 and 0.85 mg/kg produced Cmax values of 12.14 and 17.44 ng/mL respectively, with median Tmax of 1.5 hours and peak subjective effects at 1.5–2 hourssupported

Cmax for DMT: 12.14 ng/mL (low dose) and 17.44 ng/mL (high dose). Tmax median 1.5h both doses. Peak subjective effects 1.5-2h. pmid:12660312

PBPK models confirm that harmine markedly enhances DMT bioavailability through MAO-A inhibition in liver and lungs.supported

Harmine inhibits DMT metabolism via MAO-A in liver and lungs. kfaf118

PBPK models confirm that harmine markedly enhances DMT bioavailability through MAO-A inhibition in liver and lungs.supported

Harmine markedly enhanced DMT bioavailability and prolonged absorption. j.biopha.2025.118329

The primary metabolic pathway is MAO-A-mediated oxidative deamination to indole-3-acetic acid (3-IAA)supported

DMT metabolized to 3-indole-acetic acid (3-IAA) by MAO... MAO-A inhibition by harmala alkaloids prevents first-pass degradation to 3-IAA. ph13110334

The primary metabolic pathway is MAO-A-mediated oxidative deamination to indole-3-acetic acid (3-IAA)supported

Oral route: no psychotropic effects, 97% IAA in urine. dta.1685

A secondary CYP-mediated pathway produces DMT-N-oxide, with CYP2D6 as the primary enzyme and CYP2C19 contributing. In vitro clearance of DMT is reduced by MAO-A inhibition, CYP2D6 inhibition, and to a lesser extent CYP2C19 inhibitionsupported

In vitro: MAO-A primary clearance, CYP2D6 and CYP2C19 also involved. s13318-023-00822-y

A secondary CYP-mediated pathway produces DMT-N-oxide, with CYP2D6 as the primary enzyme and CYP2C19 contributing. In vitro clearance of DMT is reduced by MAO-A inhibition, CYP2D6 inhibition, and to a lesser extent CYP2C19 inhibitionsupported

In vitro: MAO-A primary clearance, CYP2D6 and CYP2C19 also involved. s13318-023-00822-y

The strong CYP2D6 inhibitors fluoxetine and paroxetine are predicted by PBPK modeling to increase DMT systemic exposure when co-administered with ayahuasca, compounding pharmacodynamic serotonin syndrome risk.supported

PBPK models to predict SSRI (fluoxetine, paroxetine as CYP2D6 inhibitors) coadministration impact on DMT and harmine systemic exposure. Relevant to serotonin syndrome risk. fmolb.2026.1768402

Claim in safety — inconclusiveinconclusiveworking →

No human fatalities attributed to DMT alone have been documented in the published literaturesupported

Mildly to rarely severe adverse effects; no dependence. ph13110334

Claim in safety — inconclusiveinconclusiveworking →

SPL026 trial: 24 psychedelic-naive healthy subjects received IV DMT fumarate (9–21.5 mg, 10-minute infusion). No serious adverse events at any dose level.supported

Phase 1 SPL026 trial (NCT04673383). No serious adverse events... Psychedelic-naive healthy participants. fpsyt.2023.1305796

Claim in safety — inconclusiveinconclusiveworking →

Extended state protocol: 11 healthy volunteers received bolus plus 30-minute continuous infusion. Anxiety ratings remained low; heart rate habituated within 15 minutes.supported

Bolus + constant-rate infusion to extend DMT experience for 30 min. Eleven healthy volunteers. Anxiety remained low, HR habituated within 15 min. 02698811231196877

Strassman (1994) documented dose-dependent increases in heart rate, systolic and diastolic blood pressure, rectal temperature, and pupillary diameter following IV administrationsupported

Dose-response data for IV DMT fumarate neuroendocrine, cardiovascular, autonomic, and subjective effects. archpsyc.1994.03950020021001

Oral ayahuasca produces moderate sympathomimetic effects: diastolic blood pressure increased by 9 mmHg at the higher dose, with moderate increases in systolic blood pressure and heart ratesupported

Diastolic BP increased 9 mmHg at high dose; systolic BP and HR moderately increased. pmid:12660312

Oral ayahuasca produces moderate sympathomimetic effects: diastolic blood pressure increased by 9 mmHg at the higher dose, with moderate increases in systolic blood pressure and heart ratepartially supported

Mild sympathomimetic effects... Milder effects on pupil than amphetamine. jcp.0b013e31823607f6

Anxiety and loss-of-control sensations are common at hallucinogenic doses, particularly with IV or smoked administration where onset is measured in secondssupported

Psychological effects began almost immediately after IV administration... loss of control and dissociated state. archpsyc.1994.03950020022002

Claim in safety — inconclusiveinconclusiveworking →

Claim in safety — inconclusiveinconclusiveworking →

A longitudinal study of 127 regular ayahuasca users (twice monthly or more) versus 115 controls found no evidence of psychological maladjustment, mental health deterioration, or cognitive impairment over one yearsupported

Longitudinal study of 127 regular ayahuasca users vs 115 controls... No evidence of psychological maladjustment, mental health deterioration or cognitive impairment. journal.pone.0042421

During continuous IV infusion, moderate acute tolerance to subjective effects develops despite rising plasma DMT concentrations, consistent with 5-HT2A receptor desensitization during sustained agonist exposuresupported

Plasma DMT increased consistently starting 10 min; psychological effects plateaued suggesting acute psychological tolerance during continuous infusion. 02698811231196877

During continuous IV infusion, moderate acute tolerance to subjective effects develops despite rising plasma DMT concentrations, consistent with 5-HT2A receptor desensitization during sustained agonist exposuresupported

Moderate acute tolerance observed. s41386-024-02041-8

The absence of tolerance with sequential bolus dosing has been reported in Strassman's original research program, a finding consistent with DMT's very short receptor occupancy time (half-life 9–12 minutes) — likely insufficient to trigger receptor internalization between dosessupported

Mean elimination half-life 9-12 min... Rapid peak and clearance. s13318-023-00822-y

Claim in safety — inconclusiveinconclusiveworking →

No physical or psychological dependence has been documented in clinical trials, survey literature, or longitudinal studies of regular ayahuasca userssupported

Mildly to rarely severe adverse effects; no dependence. ph13110334

SSRIs present a dual-mechanism risk with ayahuasca: (1) pharmacokinetic — strong CYP2D6 inhibitors (fluoxetine, paroxetine) increase DMT plasma concentrations; (2) pharmacodynamic — combined serotonin reuptake inhibition and MAO-A inhibition produce dangerous 5-HT accumulationsupported

PBPK models to predict SSRI (fluoxetine, paroxetine as CYP2D6 inhibitors) coadministration impact on DMT and harmine systemic exposure. Relevant to serotonin syndrome risk. fmolb.2026.1768402

Claim in safety — inconclusiveinconclusiveworking →

Concurrent MAOI + serotonergic medications: When DMT is administered via ayahuasca (with beta-carboline MAO inhibitors), any concurrent serotonergic medication — SSRIs, SNRIs, tramadol, St. John's wort — creates potentially fatal serotonin syndrome risk. This interaction is well-characterized mechanistically and confirmed by PBPK modeling.supported

PBPK models to predict SSRI (fluoxetine, paroxetine as CYP2D6 inhibitors) coadministration impact on DMT and harmine systemic exposure. Relevant to serotonin syndrome risk. fmolb.2026.1768402

Cardiovascular disease: Transient but meaningful increases in heart rate and blood pressure are documented in healthy volunteers at both IV and oral doses. Uncontrolled hypertension, unstable angina, recent myocardial infarction, and severe heart failure constitute relative contraindications, though DMT has not been studied in these populations.supported

Dose-response data for IV DMT fumarate neuroendocrine, cardiovascular, autonomic, and subjective effects. archpsyc.1994.03950020021001

Cardiovascular disease: Transient but meaningful increases in heart rate and blood pressure are documented in healthy volunteers at both IV and oral doses. Uncontrolled hypertension, unstable angina, recent myocardial infarction, and severe heart failure constitute relative contraindications, though DMT has not been studied in these populations.supported

Diastolic BP increased 9 mmHg at high dose; systolic BP and HR moderately increased. pmid:12660312

Smoked or intravenously administered, DMT produces a complete psychedelic state lasting 5–20 minutes — the shortest of any classical serotonergic psychedelic — with an elimination half-life of 9–12 minutessupported

Mean elimination half-life 9-12 min... Rapid peak and clearance. s13318-023-00822-y

The compound occupies a singular position in psychedelic pharmacology as a putative endogenous neuroregulator: it is biosynthesized in mammalian brain tissue, functions as an endogenous sigma-1 receptor agonist, and may serve as the natural ligand for intracellular 5-HT2A receptorssupported

First report of DMT in rat pineal gland microdialysate using LC/MS/MS. bmc.2981

The compound occupies a singular position in psychedelic pharmacology as a putative endogenous neuroregulator: it is biosynthesized in mammalian brain tissue, functions as an endogenous sigma-1 receptor agonist, and may serve as the natural ligand for intracellular 5-HT2A receptorssupported

Indicates DMT is an endogenous sigma-1 receptor agonist. science.1166127

The compound occupies a singular position in psychedelic pharmacology as a putative endogenous neuroregulator: it is biosynthesized in mammalian brain tissue, functions as an endogenous sigma-1 receptor agonist, and may serve as the natural ligand for intracellular 5-HT2A receptorssupported

DMT proposed as possible endogenous ligand. science.adf0435

DMT acts as a partial agonist at the serotonin 5-HT2A receptor — its primary psychedelic mechanism — with lower binding affinity than lsd but sufficient to produce full hallucinogenic effects at doses ≥0.2 mg/kg IVsupported

DMT: lower 5-HT2A affinity than LSD, interacted with SERT, partial/full 5-HT2A agonist. j.euroneuro.2016.05.001

Critically, neuroplasticity is promoted through activation of intracellular 5-HT2ARs on the Golgi apparatus rather than cell-surface receptorssupported

Intracellular 5-HT2ARs mediate plasticity-promoting properties of psychedelics... Location bias in 5-HT2AR signaling identified. science.adf0435

Secondary targets include sigma-1 receptors and serotonin/vesicular monoamine transporters, where DMT behaves as a substrate rather than an inhibitor.supported

High binding-to-uptake ratios support DMT is a transporter substrate not blocker at both SERT and VMAT2. s00702-009-0308-8

The experience at hallucinogenic doses is characterized by vivid geometric visuals, entity encounters (reported in 45.5% of inhaled experiences), ego dissolution, and features phenomenologically overlapping with near-death experiencessupported

Entity encounters 45.5%. Fractals/patterns dominant visual... Features of mystical experience and ego dissolution common. s41598-022-11999-8

No human fatalities have been attributed to DMT alone, and Phase 1 trials at doses up to 21.5 mg IV report no serious adverse eventssupported

No serious adverse events. 21.5 mg dose most likely to provide intense, tolerated experience. fpsyt.2023.1305796

During continuous IV infusion, moderate acute tolerance develops consistent with 5-HT2A receptor desensitization, though sequential bolus dosing may not produce tolerance due to insufficient receptor occupancy timesupported

Moderate acute tolerance observed. s41386-024-02041-8

Good et al. (2023) published the first comprehensive human IV DMT PK characterization using SPL026 (DMT fumarate) administered as a 10-minute infusion to 24 healthy, psychedelic-naive subjects at doses of 9, 12, 14, 18, and 21.5 mg freebase equivalent.supported

24 healthy subjects received escalating IV DMT (9-21.5 mg freebase as 10-min infusion). s13318-023-00822-y

Erne et al. (2025) extended PK characterization to continuous IV infusions (0.6–2.4 mg/min over 120 minutes) in 22 healthy participantssupported

22 healthy participants received placebo and DMT (0.6-2.4 mg/min) over 120 min infusion. s41386-024-02041-8

A novel buccal DMT/harmine formulation (120 mg DMT + 180 mg harmine) achieved plasma Cmax of approximately 33 ng/mL.supported

16 healthy participants received 6 dose combinations of buccal DMT (0-120 mg) and harmine (0-180 mg). Peak DMT Cmax ~33 ng/mL. j.biopha.2025.117908

PBPK modeling by Ribeiro et al. (2026) predicts clinically significant pharmacokinetic interactions between ayahuasca and SSRIs that are strong CYP2D6 inhibitors (fluoxetine, paroxetine), raising both DMT plasma concentrations and serotonin syndrome risksupported

PBPK models to predict SSRI (fluoxetine, paroxetine as CYP2D6 inhibitors) coadministration impact on DMT and harmine systemic exposure. Relevant to serotonin syndrome risk. fmolb.2026.1768402

Riba et al. (2003) characterized oral DMT PK under MAO-A inhibition via ayahuasca:supported

Double-blind placebo-controlled RCT. 18 volunteers with prior psychedelic experience received oral ayahuasca... Cmax for DMT: 12.14 ng/mL (low dose) and 17.44 ng/mL (high dose). pmid:12660312

PBPK models by Wittayakarn et al. (2025) and Abelo et al. (2025) confirm that harmine dramatically enhances DMT bioavailability through MAO-A inhibition in both hepatic and pulmonary first-pass sitessupported

Harmine markedly enhanced DMT bioavailability and prolonged absorption. j.biopha.2025.118329

The dominant pathway is MAO-A-catalyzed oxidative deamination producing indole-3-acetic acid (3-IAA), which accounts for 97% of urinary metabolites after oral administration without MAO inhibitionsupported

DMT metabolized to 3-indole-acetic acid (3-IAA) by MAO... MAO-A inhibition by harmala alkaloids prevents first-pass degradation to 3-IAA. ph13110334

After oral administration (without MAO inhibition), 3-IAA accounts for 97% of recovery, indicating near-complete MAO-A-mediated presystemic clearance.supported

Oral route: no psychotropic effects, 97% IAA in urine. dta.1685

In 24 psychedelic-naive healthy subjects receiving DMT fumarate by 10-minute IV infusion at doses of 9–21.5 mg freebase equivalent, no serious adverse events occurredsupported

No serious adverse events... Psychedelic-naive healthy participants. fpsyt.2023.1305796

Erne et al. (2025) reported results from continuous IV infusions (0.6–2.4 mg/min over 120 minutes) in 22 healthy participantssupported

22 healthy participants received placebo and DMT (0.6-2.4 mg/min) over 120 min infusion. s41386-024-02041-8

NCT05780216 investigated a buccal formulation combining DMT (120 mg) with harmine (180 mg) in healthy volunteerssupported

16 healthy participants received 6 dose combinations of buccal DMT (0-120 mg) and harmine (0-180 mg). j.biopha.2025.117908

Claim in clinical-evidence — inconclusiveinconclusiveworking →

NCT05780216 investigated a buccal formulation combining DMT (120 mg) with harmine (180 mg) in healthy volunteerssupported

Ayahuasca-inspired DMT/harmine formulation via buccal microcarrier delivery. PK-PD interactions characterized. pyaf001

Pharmacokinetics were dose-proportional with a mean elimination half-life of 9–12 minutessupported

Mean elimination half-life 9-12 min. s13318-023-00822-y

Luan et al. (2024) assessed the psychological and physiological effects of extended DMT states (bolus plus 30-minute continuous infusion) in 11 healthy volunteerssupported

Bolus + constant-rate infusion to extend DMT experience for 30 min. Eleven healthy volunteers. 02698811231196877

Detection of DMT in human urine during the 1960s and 1970s generated early speculation about a possible role in schizophrenia and endogenous psychosissupported

Historical overview of endogenous DMT research: biosynthesis and metabolism in brain and peripheral tissues, detection in body fluids and brain, sites of action, physiological and therapeutic roles. fnins.2018.00536

In 2013, Barker et al. achieved the first direct detection of DMT in rat pineal gland microdialysate, providing physiological evidence for active endogenous productionsupported

First report of DMT in rat pineal gland microdialysate using LC/MS/MS. bmc.2981

The identification in 2023 of intracellular 5-HT2A receptors as the site of psychedelic-driven neuroplasticity prompted the proposal that DMT may function as the endogenous ligand for these receptorssupported

DMT proposed as endogenous ligand for intracellular 5-HT2A in Golgi. Neuroplastogen role. j.pnpbp.2025.111259

The resulting dose-response studies, published in Archives of General Psychiatry, established the Hallucinogen Rating Scale (HRS) and remain foundational references for DMT's subjective and physiological effectssupported

HRS scale presented. Psychological effects began almost immediately after IV administration, peaked at 90-120 seconds, almost resolved by 30 minutes. archpsyc.1994.03950020022002

Contemporary DMT research accelerated from 2018, led by Timmermann and Carhart-Harris at Imperial College London, who published landmark EEG and combined EEG-fMRI studies of intravenous DMTsupported

13 healthy participants (6F, 7M), IV DMT vs placebo. EEG: marked reduction in alpha/beta oscillations, robust increase in signal diversity. s41598-019-51974-4

Small Pharma's SPL026 program (NCT04673383) completed Phase 1 safety and pharmacokinetic studies in 2023supported

Phase 1 component of Phase I/IIa trial (NCT04673383). 24 healthy subjects received escalating IV DMT. s13318-023-00822-y

As of 2026, multiple Phase 2 trials are active or planned for major depressive disorder and treatment-resistant depression, and novel delivery systems — including buccal formulations combining DMT with harmine and transdermal preparations — are under clinical investigation.supported

Four Phase II studies with 5-MeO-DMT and one with DMT for TRD; two Phase II studies with DMT fumarate for MDD. biomedicines14030506

The 9–12 minute elimination half-life and 5–20 minute subjective experience (IV/smoked) contrast sharply with psilocybin (4–6 hours), lsd (8–12 hours), and mescaline (8–12 hours)supported

Mean elimination half-life 9-12 min... Rapid peak and clearance. s13318-023-00822-y

Ramaekers et al. (2025) have argued that DMT's ultra-short action may offer therapeutic advantages: shorter clinical sessions, reduced staffing requirements, and potentially lower psychological risk from prolonged altered states.supported

Short interventions (15-30 min) safe and tolerated, marked improvement within 24h... Benefits: flexible single-day dosing. appi.ajp.20230890

DMT's unique polypharmacological profile — combining 5-HT2A partial agonism, sigma-1 agonism, monoamine transporter substrate behavior, and TAAR activation — has no direct parallel among classical psychedelics.supported

Review of DMT's unique properties and therapeutic potential. fpsyt.2024.1485337

DMT stands alone among classical psychedelics as a confirmed endogenous compound in mammalian tissuesupported

Review of endogenous DMT brain concentrations in rodents. j.pnpbp.2025.111259

While endogenous production has been suggested for some other tryptamines, only DMT has documented sigma-1 agonism confirmed in knockout models and a plausible role as the natural ligand for intracellular 5-HT2A receptorssupported

Intracellular 5-HT2ARs as therapeutic target; DMT proposed as possible endogenous ligand. science.adf0435

Timmermann et al. (2023) conducted the most comprehensive neuroimaging study of DMT to date, combining simultaneous EEG and fMRI in 20 healthy volunteers receiving IV DMTsupported

20 healthy volunteers, within-subjects placebo-controlled. Simultaneous EEG-fMRI during IV 20 mg DMT. pnas.2218949120

Eckernas et al. (2023) developed EEG pharmacokinetic-pharmacodynamic models demonstrating concentration-dependent EEG changes, providing a potential biomarker for clinical dose optimization.supported

Concentration-dependent EEG effects. Relevant for biomarker selection in clinical DMT development. psp4.12933

The sigma-1 receptor provides a parallel neuroprotective pathway: Szabo et al. (2021) demonstrated that DMT attenuated spreading depolarization and neurodegeneration in ischemic rat brain specifically through sigma-1 activation.supported

DMT mitigated spreading depolarizations via sigma-1R in rat ischemia model. Reduced apoptotic/ferroptotic cells. j.neuropharm.2021.108612

Endogenous function: What is the physiological role of endogenous DMT? The discovery of intracellular 5-HT2A receptors inaccessible to serotonin but accessible to DMT suggests a specific neuroregulatory function, but no causal demonstration of endogenous DMT activating these receptors in vivo has been published.supported

Review of endogenous DMT brain concentrations in rodents. Discusses intracellular sigma-1 and 5-HT2A binding. DMT proposed as endogenous ligand for intracellular 5-HT2A in Golgi. j.pnpbp.2025.111259

Dissociability of psychedelic and neuroplastic effects: Can DMT's neuroplastic (therapeutic) effects be achieved at sub-psychedelic doses, or does the subjective experience mediate the therapeutic outcome? Transdermal formulations achieving sub-hallucinogenic plasma levels (60 ng/mL or below) are designed to test this question.supported

77% bioavailability vs IV at sub-hallucinogenic plasma concentrations not exceeding 60 ng/mL. j.ejps.2024.106803

The freebase exhibits low lipophilicity by experimental determination, with low plasma protein binding consistent with rapid tissue distributionsupported

Low lipophilicity, low plasma protein binding. Rapid peak and clearance. s13318-023-00822-y

Barker et al. (2013) detected DMT in rat pineal gland microdialysate by LC/MS/MS, and Barker (2025) characterized DMT concentrations and distribution across rodent brain regionssupported

First report of DMT in rat pineal gland microdialysate using LC/MS/MS. bmc.2981

The biosynthetic pathway from tryptamine via indolethylamine N-methyltransferase (INMT) has been assumed, though INMT knockout studies suggest alternative enzymatic routes may exist.supported

Rat INMT insufficient for NMT or DMT biosynthesis. Suggests alternative enzymatic pathway for DMT biosynthesis. s41598-023-27538-y

The discovery that psychedelic-driven neuroplasticity occurs through intracellular rather than cell-surface 5-HT2A receptors represents a paradigm shift in understanding DMT's mechanismsupported

Intracellular 5-HT2ARs mediate plasticity-promoting properties of psychedelics. Serotonin does not engage similar plasticity mechanisms. Location bias in 5-HT2AR signaling identified. science.adf0435

Fontanilla et al. (2009) demonstrated DMT's endogenous sigma-1 receptor agonism in a study published in Sciencesupported

Indicates DMT is an endogenous sigma-1 receptor agonist. science.1166127

Szabo et al. (2021) confirmed sigma-1-mediated neuroprotection in a rat cerebral ischemia model, where DMT attenuated spreading depolarization and restrained neurodegeneration.supported

DMT mitigated spreading depolarizations via sigma-1R in rat ischemia model. Reduced apoptotic/ferroptotic cells. j.neuropharm.2021.108612

The phenomenological overlap with near-death experiences is unique among classical psychedelics and has been confirmed in placebo-controlled studies.supported

Within-subjects placebo-controlled study... Significant increases in NDE phenomenological features after DMT. Significant overlap with 'actual' NDE experiencers across nearly all features. fpsyg.2018.01424